Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Issue : PJ September 2015 online

Sort by: Newest first Oldest first A-Z Z-A

  • England’s CPO Keith Ridge (pictured) said the expansion of patient care and a focus on medicines optimisation are a “dead cert” for the future of pharmacy

    Chief pharmacists: pharmacy’s future is ‘clinical and digital’ Subscription

    22 SEP 2015 17:13 By Stephen Robinson

    The pharmacy workforce must embrace clinical practice in the next few years amid advancements in medical and dispensing technologies, according to the UK’s chief pharmaceutical officers.

  • Local practice forum events: 23 September – 4 November 2015 Subscription

    22 SEP 2015 15:01

    Wednesday 23 September: Sheffield, Rotherham and Barnsley

  • Side effects and interactions for Fareston Subscription

    22 SEP 2015 14:45

    The summary of product characteristics (SPC) for Fareston (toremifene; Orion) now states that cases of liver injury, including elevation of liver enzymes, hepatitis and jaundice, have been reported with toremifene. Additionally, the amount of lactose per tablet has been amended from 30mg to 28.5mg. The updated SPC also states that, theoretically, the metabolism of toremifene is inhibited by drugs known to inhibit the CYP3A enzyme system. Examples of such drugs are antifungal imidazoles, ...

  • Reduced shelf life for Cayston Subscription

    22 SEP 2015 14:44

    The shelf life for Cayston (aztreonam) solvent ampoule has been reduced from four to three years. 

  • Extra needle in Zypadhera Subscription

    22 SEP 2015 14:32

    According to the updated summary of characteristics for Zypadhera (olanzapine pamoate monohydrate; Eli Lilly), the product now comes with two 19-gauge, 50mm hypodermic safety needles.

  • Lacri-Lube ointment recall Subscription

    22 SEP 2015 14:30

    The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for specific batches of Lacri-Lube eye ointment (Allergan). This is because black particles may be present on or around the nozzle of the tube. More information about the recall is available from the MHRA ...

  • Movicol Plain shelf life extended Subscription

    22 SEP 2015 14:30

    The shelf-life for Movicol Plain (macrogol, sodium chloride, sodium hydrogen carbonate, potassium chloride; Norgine), once reconstituted, has been extended from 6 hours to 24 hours, according to the updated summary of product characteristics.

  • NHS Atlas of Variation 2015 published Subscription

    22 SEP 2015 14:28

    The latest NHS Atlas of Variation, launched by Public Health England, NHS Right Care and NHS England, is now available to download from the NHS Right Care website. The atlas is made up of a series of maps that indicate the difference in the provision of care across England. 

  • Pulmonary arterial hypertension with Pegasys Subscription

    22 SEP 2015 14:27

    Pulmonary arterial hypertension has been added as a adverse event with unknown frequency in the summary of product characteristics for Pegasys (peginterferon alfa-2a; Roche). It states that cases of pulmonary arterial hypertension have been reported in patients with risk factors such as portal hypertension, HIV infection and cirrhosis.

  • Abraxane rejected by NICE Subscription

    22 SEP 2015 14:12

    The National Institute for Health and Care Excellence (NICE) has issued final draft guidance that does not recommend Abraxane (nab-paclitaxel; Celgene) for the treatment of metastatic, previously untreated pancreatic adenocarcinoma. This decision has been made on the grounds that there is minimal benefit to the patient compared with existing treatments so the cost is not justified. Consultees have two weeks to notify NICE of any factual ...

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.